Search
Displaying 161–170 of 609 for “retinal diseases”
-
Kiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch Therapy
Research NewsThe company’s molecule is designed to restore some vision to people with ultra-low or no vision caused by advanced retinitis pigmentosa and other retinal diseases.
-
Research News
Precise and Sensitive Outcome Measures are Essential for Getting Vision Treatments through Clinical Trials
-
Foundation News
The four-year study will inform clinical trial design for emerging USH3 therapies.
-
Eye on the Cure Podcast | Episode 63: Dr. Hema Ramkumar
Eye on the CureHema Ramkumar, MD, a retinal specialist, surgeon, and founder of the company Oculogenex, talks with host Ben Shaberman about her emerging therapy that targets mitchondria to slow the progression of intermediate dry age-related macular degeneration and potentially other retinal diseases. She also discusses her experiment that will put mice in space so researchers can gain a better understanding of retinal degeneration.
-
Eye on the Cure Podcast | Episode 55: Omar Mahroo, MB, PhD
Eye on the CureOmar Mahroo, MB, PhD, talks with host Ben Shaberman about electrophysiological testing for the retina, namely the electroretinogram (ERG), and its important role in evaluating and diagnosing inherited retinal diseases. Dr. Mahroo is a consultant ophthalmologist and retinal specialist at Moorfields Eye Hospital and St. Thomas’ Hospital in London, and Professor of Retinal Neuroscience at University College London.
-
Foundation Invests $5.5 Million in Seven New Translational Research Projects
Research NewsProjects target a variety of conditions including: age-related macular degeneration, Stargardt disease, retinitis pigmentosa, and Usher syndrome type 3A
-
Individual Investigator Research Award (IIRA)
Individual Investigator Research Awards are designed to concentrate research in areas with the greatest potential to move toward treatments and cures for the inherited orphan retinal degenerative diseases and dry age-related macular degeneration. This award provides approximately $100,000 per year up to three (3) years. These opportunities seek candidates that hold a Ph.D., M.D., M.D./Ph.D., D.M.D., D.V.M., D.O., O.D., or equivalent degree and have a faculty position or equivalent at a domestic or foreign: non-profit organization, or public or private institution, such as a university, college, medical school, hospital, research institute, or laboratory. Individuals from underrepresented racial, ethnic and gender groups, as well as individuals with disabilities, are always encouraged to apply.
-
Disease
X-linked retinoschisis (XLRS) is an inherited retinal diseasing causing vision loss due to splitting of the layers of the retina.
-
FFB-CRI Investing $7.5 Million in Emerging Therapy for USH2A
Research NewsThe Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) has entered into a partnership with ProQR to develop a retinal therapy for people with Usher syndrome type 2A (USH2A) caused by mutations in exon 13 of the USH2A gene.
-
Optogenetic Therapy Takes First Step Forward in Clinical Trial
Research NewsRetroSense’s optogenetic therapy is designed to restore vision to people who are completely blind from retinal degenerative diseases such as retinitis pigmentosa by bestowing light sensitivity to retinal ganglion cells, which survive after photoreceptors, the cells that make vision possible, are lost.
%20(12).png)
